Neuropace, Inc. Common Stock NPCE
Analyst Ratings
- Consensus
- Moderate Buy — 4 Buy · 2 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $15.67 (+107.2% upside)
Key Stats
- Today's Range
- $5.46 – $7.71
- 50-Day Range
- $5.46 – $15.10
- 52-Week Range
- $5.46 – $19.60
- Volume
- 6.11 million shs
- Average Volume
- 318K shs
- Market Cap
- $412.58 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.24%
- Days to Cover
- 1.00
About Neuropace, Inc. Common Stock
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Related Stocks
Compare head-to-head: NPCE vs SYK·NPCE vs BSX·NPCE vs MDLN·NPCE vs RMD
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.